Autoimmune Uveitis. Review
https://doi.org/10.18008/1816-5095-2019-1-5-11
Abstract
For many years in ophthalmology there is a complex intractable problem associated with inflammation of the vascular membrane of the eye, the so-called uveitis. Experts around the world are trying to understand this heterogeneous pathology of the visual organ, in a short time, which can lead to a sharp decrease in visual acuity, the development of severe complications and further disability. The number of patients with inflammation of the vascular tract is growing rapidly every year, the age is younger. The clinical picture of this pathology has changed slightly. Often began to manifest itself in two radically different directions. It proceeds as a sluggish form or vice versa manifests itself more aggressively with the rapid development of clinical manifestations in a short time. Currently, there is evidence of endogenous causes of uveitis.
The article provides a review of the literature summarizing modern views on the problem of autoimmune uveitis. New factors affecting the etiology, pathogenesis of the disease, some aspects of therapy are considered. In addition, the main experimental models of autoimmune diseases of the vascular tract of the eye are analyzed.
About the Authors
A. N. Plekhanov
Тhе Medical Institute of the Buryat State University
The Clinical Hospital at the Ulan-Ude station Russian Railways
Russian Federation
Russian Federation
MD, Head of the Department of Faculty Surgery, head physician
Oktyabrskaya str., 36-А, Ulan-Ude, 670002, Republic of Buryatia, Russia
Komsomolskaya str., 1-b, Ulan-Ude, 670002, Republic of Buryatia, Russia
A. S. Fomina
Тhе Medical Institute of the Buryat State University
Baikal Branch “State Scientific and Production Center of Fishery”
Russian Federation
Russian Federation
PhD, Senior Lecturer, scientific researcher
Oktyabrskaya str., 36-А, Ulan-Ude, 670002, Republic of Buryatia, Russia
Khakhalova str., 4-b, 670034, Ulan-Ude, Republic of Buryatia, Russia
O. P. Sverkunova
Тhе Medical Institute of the Buryat State University
The Clinical Hospital at the Ulan-Ude station Russian Railways
Russian Federation
Russian Federation
PhD, Senior Lecturer, doctor of clinical and diagnostic laboratory
Oktyabrskaya str., 36-А, Ulan-Ude, 670002, Republic of Buryatia, Russia
Komsomolskaya str., 1-b, Ulan-Ude, 670002, Republic of Buryatia, Russia
J. V. Ivanova
Тhе Medical Institute of the Buryat State University
The Republican Clinical Hospital named after N.A. Semashko.
Russian Federation
Russian Federation
Postgraduate, ophthalmologist of the department of eye microsurgery for adults
Oktyabrskaya str., 36-А, Ulan-Ude, 670002, Republic of Buryatia, Russia
Pavlova str., 12, Ulan-Ude, 670031 Republic of Buryatia, Russia
References
1. Maracheva N.M. Posttraumatic uveitis flow at patients with penetrating wound of an eyeball depending on localization of a penetrating wound in the early and remote period of trauma. Bulletin of the South Ural State University = Vestnik Yuzhno-Ural’skogo Universiteta. 2010;37:72–75 (in Russ).
2. Trunov N.N. Imbalans cytokines in the tear fluid in patients with autoimmune uveitis. Annals of Orenburg State University = Vestnik Orenburgskogo gosudarstvennogo universiteta. 2013;4:270–274 (in Russ).
3. Chang J.H., Wakefield D. Uveitis: a global perspective. Ocul. Immunol. Inflamm. 2002;10:263–279. DOI: 10.1076/ocii.10.4.263.15592
4. The World Health Report, WHO (2010) Global data on visual impairments. http://www.who.int/blindness/ GLOBALDATAFINALforweb.pdf. Accessed 21 Jan 2014.
5. Bodaghi B., Cassoux N., Wechsler B., Hannouche D., Fardeau C., et al. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore). 2001;80:263–270.
6. Grange L.K., Kouchouk A., Dalal M.D., Vitale S., Nussenblatt R.B., et al. Neoplastic masquerade syndromes in patients with uveitis. Am J Ophthalmol. 2013;157. DOI: 10.1016/j.ajo.2013.11.002
7. Edmunds L., Elswood J., Calin A. New light on uveitis in ankylosing spondylitis. Rheumatol. 1991;18:50.
8. Edelsten C. Epidemiology of visual loss in pediatric uveitis. XXXIX International Congress of ophthalmology. Sydney, 2002:138.
9. Julian K. Uveitis Related to Juvenile Idiopathic Arthritis: Familial Cases and Possible Genetic Implicationin the Pathogenesis: A Cohort Study. Ocular Immunology &Inflammation. 2010; 3:172–177.
10. Katargina L.A., Khvatova A.V. Endogenous uveitis in children and adolescents. Moscow, Medicine: 2000. 320 p. (in Russ).
11. Chesnokova N.B., Katargina L.A., Kuznetsova T.P. The antioxidant activity of tears in the prognosis of endogenous uveitis. Manual for physicians. Moscow, 2003. 18 p. (in Russ).
12. Katznelson L.A., Tankovskiy V.E. Uveitis (clinic, treatment). Мoscow: 4th branch Voenizdat; 2003 (in Russ).
13. Drozdova E.A. Uveitis in rheumatic diseases. Moscow, Publisher T/T; 2010:160 (in Russ).
14. Yadykina E.V. Predisposing risk factors for the development of uveitis related to juvenile idiopathic arthritis. Bashkortostan Medical Journal = Meditsinskiy vestnik Bashkortostana. 2014; 9:2:190–193 (in Russ).
15. Suarez-Figueroa M., Contreras I., Noval S. Side-effects of triamcinolone in young patients. Arch. Soc. Esp. Oftalmol. 2006;81(7):405–407. DOI: 10.4321/S0365-66912006000700009
16. Senchenko N.Y., Shuko A.G., Malyshev V.V. Uveitis: A Guide. (Series “Library medical specialist”). 2014. 160 p. (in Russ).
17. Nussenblatt R.B. The natural history of uveitis. Int Ophthalmol. 1990;14:303–308.
18. Moiseyev S.V. Uveitis in a rheumatologist’s practice: a role of tumor necrosis factor-a inhibitors. Modern Rheumatology = Sovremennaya revmatologiya. 2009;4:76–81 (in Russ). DOI: 10.14412/1996-7012-2009-577
19. Kamilov H.M., Fayzieva D.B. On the specific and nonspecific immune responsiveness in patients with endogenous uveitis. Оphthalmology in Russia = Oftal’mologiya. 2013;10(4):45–48 (in Russ). DOI: 10.18008/1816-5095-2013-4-45-48
20. Yun S.L., Ahjoku A.O., Cheng‑Rong Y., Charles E. Retinal cells suppress intraocular inflammation (uveitis) through production of interleukin‑27 and interleukin‑10. Immunology, 2011;132:492–500. DOI: 10.1111/j.1365-2567.2010.03379.x
21. Arkhipova L.S. Sympathetic ophthalmia (pathogenesis, morbid anatomy, clinical picture, diagnosis, treatment, prevention). Moscow — Tver; 2006. 248 p. (in Russ).
22. Rothova A., Buitenhuis H.J., Meenken C., Brinkman C.J., Linssen A., et al. Uveitis and systemic disease. Br J Ophthalmol. 1992;76:137, 141. DOI: 10.1136/bjo.76.3.137
23. Smith J.R., Hart P.H., Wiilliams K.A. Basic pathogenic mechanisms operating in experimental models of acute anterior uveitis. Immunol. Cell Biol. 1999;76:497–512. DOI: 10.1046/j.1440-1711.1998.00783
24. Kalyuzhin Z.H., Dikinov Z.H., Evsegneeva I.V. Models of intraocular inflammation. Immunopathology = Immunopatologiya. 2011;2:14–19 (in Russ).
25. Forrester J.V., Klaska I.P., Yu T., Kuffova L. Uveitis in mouse and man. Int Rev Immunol 2013;32:76, 96. DOI: 10.3109/08830185.2012.747524
26. Chen J., Qian H., Horai R., Chan C.C., Falick Y. Comparative analysis of induced vs. spontaneous models of autoimmune uveitis targeting the interphotoreceptor retinoid binding protein. PLoS One. 2013; 8:e72161. DOI: 10.1371/journal.pone.0072161
27. Mattapallil M.J., Silver P.B., Mattapallil J.J., Horai R., Karabekian Z., et al. Uveitisassociated epitopes of retinal antigens are pathogenic in the humanized mouse model of uveitis and identify autoaggressive T cells. J Immunol. 2011;187:1977–1985. DOI: 10.4049/jimmunol.1101247
28. Caspi R.R. Animal models of autoimmune and immunemediated uveitis. Drug discovery today: disease models. 2006;3(1):3–9. DOI: 10.1016/j.ddmod.2006.03.005
29. Rosenbaum J.T., McDevitt H.O., Guss R.B., Egbert P.R. Endotoxin-induced uveitis in rats as a model for human disease. Nature. 1980;286 (5773): 611–613. DOI: 10.1038/286611a0
30. Rosenzweig H.L., Martin T.M., Jann M.M. (NOD2, the gene responsible for familial granulomatous uveitis, in a mouse model of uveitis. Invest Ophthalmol Vis Sci. 2008;49(4):1518–1524. DOI: 10.1167/iovs.07-1174
31. Caspi R.R. A look at autoimmunity and inflammation in the eye. J Clin Invest. 2010;120(9):3073–3083. DOI: 10.1172/JCI42440
32. Foxman E.F., Zhang M., Hurst S.D., Muchamuel T., Shen D., Wawrousek E.F., Chan C.C., Gery I. Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation. J. Immunol. 2002;168:2483–2492. DOI: 10.4049/jimmunol.168.5.2483
33. Tang J., Zhu W., Silver P.B. Autoimmune uveitis elicited with antigen-pulsed dendritic cells has a distinct clinical signature and is driven by unique effector mechanisms: initial encounter with autoantigen defines disease phenotype. J Immunol. 2007;178 (9):5578–5587. DOI: 10.4049/jimmunol.178.9.5578
34. Hanashiro R., Fujino K., Gugunfu Y., et al. Synthetic lipid A-induced uveitis and endotoxin-induced uveitis — comparative study. Jpn. J. Ophthalmo. 1997;41(6):355– 361. DOI: 10.1016/S0021-5155(97)00079-8
35. Li Q., Peng B., Whitcup S.M., et al. Endotoxin induced uveitis in the mouse: susceptibility and genetic control. Exp. Eye Res. 1995;61(5):629–632. DOI: 10.1016/S0014-4835(05)80056-9
36. Kozak Y., Camelo S., Pla M. Pathological aspects of spontaneous uveitis and retinopathy in HLA-A29 transgenic mice and in animal models of retinal autoimmunity: relevance to human pathologies. Ophthalmic Res. 2008;40(3–4):175–180. DOI: 10.1159/000119872
37. Lu Y., He S., Jia L., et al. Two mouse models for recoverin-associated autoimmune retinopathy. Mol Vis. 2010;16:1936–1948.
38. Adamus G., Ren G., Weleber R.G. Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. BMC Ophthalmol. 2004;4:P/record No. 5.
39. DOI: 10.1186/1471-2415-4-5
40. Lu Y., Jia L., He S., Hurley M.C., et al. Melanoma-associated retinopathy: a paraneoplastic autoimmune complication. Arch Ophthalmol. 2009; 127 (12):1572–1580. DOI: 10.1001/archophthalmol.2009.311
41. Slepova O.S., Denisova E.V., Katargina L.A., Meshkova G.I. The role and characteristics of disturbances in the system of cytokines in the development of proliferative complications in children with peripheral uveitis. Ophtalmoimmunology = Оftal’moimmunologiya. 2007;1:260–264 (in Russ).
42. Chernysheva M.V., Bakhmetyev B.A., Sidorov D.V., Dianova D.G. Study of cytokines in serum of patients with inflammatory diseases of the eye. Cytokines and inflammation = Citokiny i vospalenie. 2002;2:135 (in Russ).
43. Huhtinen M. HLA-B27 typing in the categorisation of uveitis in a HLA-B27 rich population. Br. J. Ophthalmol, 2000;8–4:413–416. DOI: 10.1136/bjo.84.4.413
44. Zamecki K.J. HLA typing in uveitis: use and misuse. Am. J. Ophthalmol. 2010;2:189–193. DOI: 10.1016/j.ajo.2009.09.018
45. Bikbov M.M. Immunogenetic profile of anterior uveitis in patients with rheumatoid arthritis and bechterew’s decease. Bashkortostan Medical Journal = Meditsinskiy vestnik Bashkortostana. 2011;4:84–86 (in Russ).
46. Nussenblatt R.B., Mittal K.K., Ryan S., Green W.R., Maumenee A.E. Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness
47. to retinal S-antigen. Am J Ophthalmol. 1982;94:147, 158. DOI: 10.1136/bjophthalmol-2016-309764
48. Medjidova S.R. Modern theore of immunopathogenesis of sympathetic ophthalmia, role of immunological diagnostic methods. Оphthalmology in Russia = Oftal’mologiya. 2011;3(7):90–97 (in Russ).
49. Chan C.C., Mochizuki M. Sympathetic ophthalmia: an autoimmune ocular inflammatory disease. Springer SeminImmunopathol, 1999;21:125–134. DOI: 10.1007/BF00810245
50. Pleyer U., Liekfeld A., Baatz H., Hartmann C. Pharmakologische Modulation immunmediierter Erkrankungen des Auges. Klin. Monatsbl. Augenheilk. 1999;214:160–170.
51. Raizman M. Corticosteroid therapy of eye diseases, Arch. Ophthalmol. 1996;114:1000–1001. DOI: 10.1001/archopht
52. Kotter I., Duck H., Saal J. Therapy of Behcet’s disease. Ger. J. Ophthalmol. 1996;05:92–97.
53. Kulkarny P. Revieu: Uveitis and immunosuppressive drugs. J. of Ocular Pharmacology and Therapeutics. 2001;17:181–187. DOI: 10.1089/10807680151125537
54. Katargina L.A., Starikov A.V., Denisova E.V. The efficacy of Remicade for the treatment of uveitis associated with diseases of the joints, in children. Russian Pediatric Ophthalmology = Rossiiskaya pediatricheskaya oftal’mologiya. 2009;4:13–24 (in Russ).
55. Grus F.H., Augustin A.J., Loeffler K., Dick B., Lutz J., Pfeiffer N. Allopurinol has immunomodulating activity following topical and systemic application in experimental autoimmune uveitis. Eur. J. Ophthalmol. 2001;11(3):252–260.
56. Kurose S., Ikeda E., Tokiwa M., Hikita N., Mochizuki M. Effects of FTY 720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats. Exp. Eye Res. 2000;70(1):7–15. DOI: 10.1006/exer.1999.0777
57. Morgan J.P., Robins R.A., Dua H.S., Tighe P.J. S antigen specific effector T cell activation detected by cytokine flow cytometry. Br. J. Ophthalmol. 2002;86:517–520.
58. Godzenko A.A. Perspectives for uveitis treatment in rheumatic diseases. Modern Rheumatology = Sovremennaya revmatologiya. 2011;2:37–42 (in Russ).
59. Biester S. Adalimumab in the therapy of uveitis in childhood. British Journal of Ophthalmology. 2007;91:319–324. DOI: 10.1136/bjo.2006.103721
60. Schmeling H. Etanercept and uveitis in patients with juvenile idiopathic arthritis Rheumathology (Oxford). 2005;44:1008–1011. DOI: 10.1093/rheumatology/keh658
61. Probable diffuse retinopathy caused by adalimumab in a patient with Crohn’s disease P. Marticorena-Alvares. Journal Crohns Colitis. 2012;6(9):950–953.
62. Botsios C. Resistant Behcet disease responsive to anakinra. Annals Academy of Medicine. 2008;149: 284–286.
Review
For citations:
Plekhanov A.N., Fomina A.S., Sverkunova O.P., Ivanova J.V. Autoimmune Uveitis. Review. Ophthalmology in Russia. 2019;16(1):5-11. (In Russ.) https://doi.org/10.18008/1816-5095-2019-1-5-11
Views:
5791
Email this article 